AIM ImmunoTech Hits Key Pancreatic Cancer Trial Milestone Ahead of Schedule
Event summary
- Final subject received last dose in Phase 2 DURIPANC trial for pancreatic cancer, ahead of schedule.
- Primary endpoint analysis (Clinical Benefit Rate) expected December 2026 with topline results in Q1 2027.
- Overall Survival endpoint analysis slated for June 2027; secondary endpoints include immune profiling.
- Named Patient Program showed median Overall Survival of 34.8 months vs. 12.5 months in historical controls (subset).
- AIM plans Phase 3 trial design based on DURIPANC biomarker stratifications.
The big picture
AIM ImmunoTech's accelerated DURIPANC trial timeline underscores the urgency in addressing pancreatic cancer, a disease with limited treatment options. The focus on biomarker-driven patient selection aligns with broader oncology trends toward precision medicine, while AstraZeneca's involvement signals validation of Ampligen's immuno-oncology potential. Success here could reposition AIM as a key player in metastatic pancreatic cancer therapies.
What we're watching
- Clinical Efficacy
- Whether DURIPANC's topline results in Q1 2027 validate the Named Patient Program's survival trends.
- Regulatory Pathway
- The pace at which AIM advances toward a pivotal Phase 3 trial based on biomarker data.
- Commercial Strategy
- How AstraZeneca's collaboration shapes Ampligen's potential market positioning against Imfinzi.